Virax Biolabs (VRAX) CEO reports holdings in shares and options

Rhea-AI Filing Summary

Virax Biolabs Group Ltd Chief Executive Officer Foster James Alexander Cunliffe filed an initial statement of beneficial ownership, showing 287,987 Ordinary Shares held directly plus multiple stock option awards over additional Ordinary Shares. These options carry exercise prices ranging from $50.00 down to $0.68 per share and expire between 2032 and 2035. Footnotes explain that the grants were made under the company’s 2023 and 2024 equity incentive plans, with vesting schedules that generally occur in equal annual installments over three years, becoming exercisable as they vest.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Foster James Alexander Cunliffe

(Last) (First) (Middle)

BIOCITY GLASGOW BO'NESS ROAD

NEWHOUSE LANARKSHIRE

(Street)

MOTHERWELL LANARKSHIRE ML1 5UH

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Virax Biolabs Group Ltd [ VRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	287,987	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	07/20/2032	Ordinary Shares	37,250	$50	D
Stock Options (right to buy)	(2)	04/18/2033	Ordinary Shares	40,000	$6	D
Stock Options (right to buy)	(3)	04/18/2034	Ordinary Shares	50,000	$0.68	D
Stock Options (right to buy)	(4)	04/08/2035	Ordinary Shares	18,025	$0.88	D
Stock Options (right to buy)	(5)	04/08/2035	Ordinary Shares	31,975	$0.88	D

Explanation of Responses:

1. On July 20, 2022, the Company granted 37,250 stock options under the Company's 2023 Equity Incentive Plan. The stock options are fully vested.

2. On April 18, 2023, the Company granted 40,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2024, 2025, and 2026. The vested portions of such options will become exercisable upon vesting.

3. On April 18, 2024, the Company granted 50,000 stock options under the Company's 2023 Equity Incentive Plan. The options vest in equal thirds on April 18 of each of 2025, 2026, and 2027. The vested portions of such options will become exercisable upon vesting.

4. On April 8, 2025, the Company granted 18,025 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027, and 2028. The vested portions of such options will become exercisable upon vesting.

5. On April 8, 2025, the Company granted 31,975 stock options under the Company's 2024 Equity Incentive Plan. The options vest in equal thirds on April 8 of each of 2026, 2027, and 2028. The vested portions of such options will become exercisable upon vesting.

	/s/ James Foster	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider ownership did Virax Biolabs (VRAX) CEO report?

Virax Biolabs CEO Foster James Alexander Cunliffe reported direct ownership of 287,987 Ordinary Shares. This reflects his existing equity stake, as disclosed in an initial beneficial ownership statement, and forms the base of his direct share position in the company.

What stock options does the Virax Biolabs CEO hold?

The CEO holds several stock options over Ordinary Shares, with exercise prices including $50.00, $6.00, $0.68, and $0.88. These option grants were awarded under Virax’s 2023 and 2024 equity incentive plans and represent potential future share acquisitions.

When do the Virax Biolabs CEO’s stock options expire?

The CEO’s stock options have expiration dates ranging from 2032 to 2035. Individual grants expire on July 20, 2032, April 18, 2033, April 18, 2034, and April 8, 2035, setting the final dates by which each grant can be exercised.

How do the Virax Biolabs CEO’s option grants vest and become exercisable?

Each option grant vests in equal thirds over three years on specified anniversary dates, such as April 18 or April 8. The footnotes state that the vested portions become exercisable upon vesting, linking exercise rights directly to this graded vesting schedule.

Under which plans were the Virax Biolabs CEO’s options granted?

The CEO’s options were granted under the 2023 Equity Incentive Plan and the 2024 Equity Incentive Plan. Earlier grants, such as the 37,250 and 40,000 option awards, reference the 2023 plan, while the 18,025 and 31,975 option grants reference the 2024 plan.

Does this Virax Biolabs filing show any recent insider buying or selling?

The disclosure lists the CEO’s existing holdings of Ordinary Shares and stock options, without recording any explicit purchases or sales. The transactions are categorized as holdings, indicating a position snapshot rather than new open-market trading activity.